This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 Nov;7(11):602.

doi: 10.1038/nrcardio.2010.148.

Prevention: Neuropsychiatric adverse effects signal the end of the line for rimonabant

PMID: 21080606
DOI: 10.1038/nrcardio.2010.148

Comment

Prevention: Neuropsychiatric adverse effects signal the end of the line for rimonabant

Alexandra King. Nat Rev Cardiol. 2010 Nov.

. 2010 Nov;7(11):602.

doi: 10.1038/nrcardio.2010.148.

Author

PMID: 21080606
DOI: 10.1038/nrcardio.2010.148

No abstract available

PubMed Disclaimer

Comment on

Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial.
Topol EJ, Bousser MG, Fox KA, Creager MA, Despres JP, Easton JD, Hamm CW, Montalescot G, Steg PG, Pearson TA, Cohen E, Gaudin C, Job B, Murphy JH, Bhatt DL; CRESCENDO Investigators. Topol EJ, et al. Lancet. 2010 Aug 14;376(9740):517-23. doi: 10.1016/S0140-6736(10)60935-X. Lancet. 2010. PMID: 20709233 Clinical Trial.

References

1. Lancet. 2010 Aug 14;376(9740):517-23 - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.